Enveric Biosciences Inc Total Liabilities
Enveric Biosciences Inc total liabilities. Based on the latest financial reports, Enveric Biosciences Inc (ENVB) has total liabilities worth $905.88K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ENVB asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Enveric Biosciences Inc (1994–2024)
Total liabilities of Enveric Biosciences Inc from 1994 to 2024. This chart illustrates how Enveric Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Enveric Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Enveric Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brain+ ApS
CO:BRAINP
|
Denmark | Dkr20.90 Million |
|
Vivanco Gruppe AG
F:VG0K
|
Germany | €23.05 Million |
|
FKS Food Sejahtera Tbk PT
JK:AISA
|
Indonesia | Rp942.71 Billion |
|
International Parkside Products Inc
V:IPD
|
Canada | CA$1.35 Million |
|
Prima Moda SA
WAR:PMA
|
Poland | zł10.61 Million |
|
CAT STRATEGIC MET.
F:8CHA
|
Germany | €1.53 Million |
|
XXL Energy Corp
V:XL
|
Canada | CA$54.49 Million |
Liability Composition Analysis (1994–2024)
This chart breaks down Enveric Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Enveric Biosciences Inc balance sheet assets.
Liquidity & Leverage Metrics
Enveric Biosciences Inc Total Liabilities Ratios Explained
Enveric Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enveric Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enveric Biosciences Inc (1994–2024)
The table below shows the annual total liabilities of Enveric Biosciences Inc from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.49 Million | -36.43% |
| 2023-12-31 | $2.34 Million | -41.35% |
| 2022-12-31 | $4.00 Million | -9.45% |
| 2021-12-31 | $4.41 Million | +547.81% |
| 2020-12-31 | $681.25K | -95.26% |
| 2019-12-31 | $14.38 Million | -23.81% |
| 2018-12-31 | $18.88 Million | -42.35% |
| 2017-12-31 | $32.75 Million | +17.61% |
| 2016-12-31 | $27.84 Million | +105.09% |
| 2015-12-31 | $13.58 Million | +151490.01% |
| 2014-12-31 | $8.96K | -63.73% |
| 2013-12-31 | $24.70K | -3.78% |
| 2012-12-31 | $25.67K | +43.43% |
| 2011-12-31 | $17.89K | -64.66% |
| 2010-12-31 | $50.64K | +326.75% |
| 2009-12-31 | $11.87K | -44.04% |
| 2008-12-31 | $21.21K | -55.73% |
| 2007-12-31 | $47.90K | -44.99% |
| 2006-12-31 | $87.08K | -51.50% |
| 2005-12-31 | $179.52K | -73.06% |
| 2004-12-31 | $666.31K | +166.77% |
| 2003-12-31 | $249.77K | -21.21% |
| 2002-12-31 | $317.01K | -7.18% |
| 2001-12-31 | $341.54K | -57.64% |
| 2000-12-31 | $806.35K | -40.26% |
| 1999-12-31 | $1.35 Million | -44.83% |
| 1998-12-31 | $2.45 Million | +49.20% |
| 1997-12-31 | $1.64 Million | +87.79% |
| 1996-12-31 | $873.32K | +24.76% |
| 1995-12-31 | $700.00K | -22.22% |
| 1994-12-31 | $900.00K | -- |
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage fo… Read more